3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
814
Uterine Cervical Neoplasms
549
Endometrial Neoplasms
467
Breast Neoplasms
227
Fallopian Tube Neoplasms
202
Colorectal Neoplasms
182
Carcinoma, Non-Small-Cell Lung
163
Neoplasms
140
Stomach Neoplasms
128
Pancreatic Neoplasms
120
Prostatic Neoplasms
109
Melanoma
108
Neoplasm Metastasis
107
Lung Neoplasms
105
Carcinoma, Ovarian Epithelial
94
Triple Negative Breast Neoplasms
92
Squamous Cell Carcinoma of Head and Neck
82
Esophageal Neoplasms
78
Head and Neck Neoplasms
77
Carcinoma, Renal Cell
76
Urinary Bladder Neoplasms
75
Uterine Neoplasms
67
Vulvar Neoplasms
66
Colonic Neoplasms
60
Uterine Cervical Dysplasia
59
Peritoneal Neoplasms
59
Carcinoma, Hepatocellular
59
Sarcoma
53
Carcinoma, Transitional Cell
49
Papillomavirus Infections
47
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gynecologic
×
1 year
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled